The GLP-1 receptor in airway inflammation in asthma: a promising novel target?

References

• Centers for Disease Control and Prevention. National diabetes statistics report, 2020. Atlanta/GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020.
   Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
   PubMed Web of Science ®Google Scholar
• Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280–1290.
   PubMed Web of Science ®Google Scholar
• Viby N-E, Isidor MS, Buggeskov KB, et al. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013;154:4503–4511.
   PubMed Web of Science ®Google Scholar
• Hur J, Kang JY, Kim YK, et al. Glucagon-like peptide 1 receptor (GLP-1R) agonist relieved asthmatic airway inflammation via suppression of NLRP3 inflammasome activation in obese asthma mice model. Pulm Pharmacol Ther. 2021;67:102003.
   PubMed Web of Science ®Google Scholar
• Nguyen D-V, Linderholm A, Haczku A, et al. Glucagon-like peptide 1: a potential anti-inflammatory pathway in obesity-related asthma. Pharmacol Ther. 2017;180:139–143.
   PubMed Web of Science ®Google Scholar
• Gou S, Zhu T, Wang W, et al. Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice. Int Immunopharmacol. 2014;22:498–504.
   PubMed Web of Science ®Google Scholar
• Zhu T, Wu X-L, Zhang W, et al. Glucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-κB (NF-κB) signaling pathway in mice. Int J Mol Sci. 2015;16:20195–20211.
   PubMed Web of Science ®Google Scholar
• Zhu T, Li C, Zhang X, et al. GLP-1 analogue liraglutide enhances SP-A expression in LPS-induced acute lung injury through the TTF-1 signaling pathway. Mediators Inflamm. 2018;2018:3601454.
   PubMed Web of Science ®Google Scholar
• Wei J-P, Yang C-L, Leng W-H, et al. Use of GLP1RAs and occurrence of respiratory disorders: a meta-analysis of large randomized trials of GLP1RAs. Clin Respir J. 2021;15:847–850.
   Web of Science ®Google Scholar
• Global Health Estimates. 2016: deaths by cause, age, sex, by country and by region, 2000-2016. Geneva: World Health Organization; 2018.
   Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–490.
   PubMed Web of Science ®Google Scholar
• Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood. 2009;113:1526–1534.
   PubMed Web of Science ®Google Scholar
• Chan BCL, Lam CWK, Tam L-S, et al. IL33: roles in allergic inflammation and therapeutic perspectives. Front Immunol. 2019;10:364.
   PubMed Web of Science ®Google Scholar
• Toki S, Goleniewska K, Reiss S, et al. Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. J Allergy Clin Immunol. 2018;142:1515–1528.e8.
   PubMed Web of Science ®Google Scholar
• Bloodworth MH, Rusznak M, Pfister CC, et al. Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology. J Allergy Clin Immunol. 2018;142:683–687.e12.
   PubMed Web of Science ®Google Scholar
• Foer D, Beeler PE, Cui J, et al. Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like peptide-1 receptor agonists. Am J Respir Crit Care Med. 2021;203:831–840.
   PubMed Web of Science ®Google Scholar
• Billington CK, Ojo OO, Penn RB, et al. cAMP regulation of airway smooth muscle function. Pulm Pharmacol Ther. 2013;26:112–120.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Capuani B, et al. Glucagon-like peptide 1 receptor: a novel pharmacological target for treating human bronchial hyperresponsiveness. Am J Respir Cell Mol Biol. 2016;55:804–814.
   PubMed Web of Science ®Google Scholar
• Lee J, Kim TH, Murray F, et al. Cyclic AMP concentrations in dendritic cells induce and regulate Th2 immunity and allergic asthma. Proc Natl Acad Sci U S A. 2015;112:1529–1534.
   PubMed Web of Science ®Google Scholar
• Körner M, Stöckli M, Waser B, et al. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med Off Publ Soc Nucl Med. 2007;48:736–743.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Calzetta L, et al. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir Med. 2019;154:86–92.
   PubMed Web of Science ®Google Scholar
• Nohara H, Nakashima R, Kamei S, et al. Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases. Biochem Biophys Res Commun. 2020;524:332–339.
   PubMed Web of Science ®Google Scholar
• Vara E, Arias-Díaz J, Garcia C, et al. Glucagon-like peptide-1 (7-36)amide stimulates surfactant secretion in human type II pneumocytes. Am J Respir Crit Care Med. 2001;163:840–846.
   PubMed Web of Science ®Google Scholar
• Xu J, Wei G, Wang J, et al. Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function. Lab Investig J Tech Methods Pathol. 2019;99:577–587.
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhang Y, Chen J, et al. Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol. 2016;791:735–740.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Tada Y, Gladson S, et al. Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition. Respir Res. 2017;18:177.
   PubMed Web of Science ®Google Scholar
• Sato T, Shimizu T, Fujita H, et al. GLP-1 receptor signaling differentially modifies the outcomes of sterile vs viral pulmonary inflammation in male mice. Endocrinology. 2020;161. DOI:https://doi.org/10.1210/endocr/bqaa201.
   Google Scholar
• Telenga ED, Tideman SW, Kerstjens HAM, et al. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. Allergy. 2012;67:1060–1068.
   PubMed Web of Science ®Google Scholar
• Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–224.
   PubMed Web of Science ®Google Scholar
• McCravy M, Ingram JL, Que LG. Dysregulated metabolism in the pathophysiology of non-allergic obese asthma. J Asthma Allergy. 2021;14:179–186.
   PubMed Web of Science ®Google Scholar
• Toki S, Newcomb DC, Printz RL, et al. Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice. Allergy. 2021. DOI:https://doi.org/10.1111/all.14879.
   Google Scholar
• Singh VP, Aggarwal R, Singh S, et al. Metabolic syndrome is associated with increased oxo-nitrative stress and asthma-like changes in lungs. PloS One. 2015;10:e0129850.
   PubMed Web of Science ®Google Scholar
• Ojima A, Ishibashi Y, Matsui T, et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltransferase-1 expression. Am J Pathol. 2013;182:132–141.
   PubMed Web of Science ®Google Scholar